We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Dr Reddys Laboratories Ltd | NYSE:RDY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.82 | -1.13% | 71.85 | 72.72 | 71.82 | 72.41 | 247,152 | 01:00:00 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January, 2024
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
Description of Exhibits | |
99.1 | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - change in Senior Management Personnel |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
Date: January 10, 2024 | By: | /s/ K Randhir Singh |
Name: K Randhir Singh | ||
Title: Company Secretary |
Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
January 10, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - change in Senior Management Personnel |
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform the following changes in the Senior Management Personnel of the Company:
a) | Dr. Ranjana Pathak has resigned from her role as Global Head of Quality and Pharmacovigilance. She will cease to be a member of the Management Council and Senior Management Personnel of the Company, effective on January 12, 2024. The resignation letter received from Dr. Pathak is annexed herewith; and |
b) | Mr. Krishna Venkatesh, currently Head Global - Injectable Operations is elevated to the role of Global Head – Quality and Pharmacovigilance, and is also inducted as a Member of the Management Council and Senior Management Personnel of the Company, effective from January 12, 2024. |
The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is given in Annexure enclosed herewith.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Encl: as above
Annexure
Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
Sl. No. | Particulars | Details |
1 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise |
a) Resignation of Dr. Ranjana Pathak from the role of Global Head of Quality and Pharmacovigilance. b) Appointment of Mr. Krishna Venkatesh as a member of the Management Council and Senior Management Personnel of the Company. |
2 | Date of appointment/ re-appointment/ cessation (as applicable); and term of appointment/ re-appointment |
a) Dr. Ranjana Pathak has resigned from her role as Global Head of Quality and Pharmacovigilance. She will cease to be a member of the Management Council and Senior Management Personnel of the Company, effective on January 12, 2024. b) Mr. Krishna Venkatesh, appointed as Global Head - Quality, and inducted as a Member of Management Council and Senior Management Personnel of the Company, effective from January 12, 2024. The Board of the Directors has approved the induction of Mr. Venkatesh as a Member of the Management Council and Senior Management Personnel of the Company on January 10. 2024. |
3 | Brief profile (in case of appointment) |
a) Not applicable b) Mr. Krishna Venkatesh has ~28 years of experience. He joined the organization in March 2010 after stints in Barr Pharma and Teva in the US. He has a rich experience in product development, technical services, process engineering, tech transfer and scale ups. In his current role he has turned around the injectables operations significantly. He holds an MS in Pharmaceutics from University of Mississippi and is a graduate from BITS Pilani. |
4 | Disclosure of relationships between directors (in case of appointment of a director) | Not applicable |
Date: January 10, 2024
To:
Dr. Reddy’s Laboratories Limited
8-2-337, Road No-3, Banjara Hills
Hyderbabad-Telangana-500034
Dear Erez,
Sub: Resignation
I hereby tender my resignation from my role of Global Head of Quality and Pharmacovigilance of Dr. Reddy’s Laboratories Limited. I would be relocating back to the US.
I sincerely appreciate the opportunity to work with the organization and have truly enjoyed the role. I wish the Company great success in the future.
Thanking you and regards,
/s/ Dr. Ranjana B Pathak | |
Dr. Ranjana B Pathak |
1 Year Dr Reddys Laboratories Chart |
1 Month Dr Reddys Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions